Abstract
Chronic myeloid leukemia (CML) is characterized by the translocation t(9;22)(q34;q11) [Philadelphia (Ph) chromosome). Although not frequently occurring, additional chromosome abnormalities (ACAs) can be detected at diagnosis and a number have been associated with an adverse cytogenetic and molecular outcome. The present study reports a case of CML presenting with the translocation t(1;11)(q21;q23) and a cryptic Ph chromosome. The presence of ACAs could generate greater genetic instability, promoting the emergence of further alterations. The present findings suggest that t(1;11) (q21;q23) can prevent a good response to tyrosine kinase inhibitor (TKI) therapy developing a primary resistance. In the present patient, at a recent follow-up, the T315I mutation was detected. This mutation confers full resistance to all available TKI, except ponatinib, which was not a therapeutic option due to comorbidities.
Author supplied keywords
Cite
CITATION STYLE
Gutiérrez, L. G., Noriega, M. F., Laudicina, A., Quatrin, M., Bengió, R. M., & Larripa, I. (2017). An unusual translocation, t(1;11)(q21;q23), in a case of chronic myeloid leukemia with a cryptic philadelphia chromosome. Oncology Letters, 13(5), 3159–3162. https://doi.org/10.3892/ol.2017.5845
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.